67 related articles for article (PubMed ID: 10628839)
1. Deregulated c-myc expression in quiescent CHO cells induces target gene transcription and subsequent apoptotic phenotype.
Fang CM; Shi C; Xu YH
Cell Res; 1999 Dec; 9(4):305-14. PubMed ID: 10628839
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc.
Sumi T; Tsuneyoshi N; Nakatsuji N; Suemori H
Oncogene; 2007 Aug; 26(38):5564-76. PubMed ID: 17369859
[TBL] [Abstract][Full Text] [Related]
3. Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts.
Solomon DL; Philipp A; Land H; Eilers M
Oncogene; 1995 Nov; 11(9):1893-7. PubMed ID: 7478619
[TBL] [Abstract][Full Text] [Related]
4. Modulation of c-Myc activity and apoptosis in vivo.
Alarcon RM; Rupnow BA; Graeber TG; Knox SJ; Giaccia AJ
Cancer Res; 1996 Oct; 56(19):4315-9. PubMed ID: 8813114
[TBL] [Abstract][Full Text] [Related]
5. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
[TBL] [Abstract][Full Text] [Related]
6. An estrogen-responsive element-targeted histone deacetylase enzyme has an antiestrogen activity that differs from that of hydroxytamoxifen.
Demirpence E; Semlali A; Oliva J; Balaguer P; Badia E; Duchesne MJ; Nicolas JC; Pons M
Cancer Res; 2002 Nov; 62(22):6519-28. PubMed ID: 12438246
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice.
Blyth K; Stewart M; Bell M; James C; Evan G; Neil JC; Cameron ER
Oncogene; 2000 Feb; 19(6):773-82. PubMed ID: 10698495
[TBL] [Abstract][Full Text] [Related]
8. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.
Greider C; Chattopadhyay A; Parkhurst C; Yang E
Oncogene; 2002 Nov; 21(51):7765-75. PubMed ID: 12420213
[TBL] [Abstract][Full Text] [Related]
9. c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli.
Kuttler F; Amé P; Clark H; Haughey C; Mougin C; Cahn JY; Dang CV; Raffeld M; Fest T
Oncogene; 2001 Sep; 20(42):6084-94. PubMed ID: 11593416
[TBL] [Abstract][Full Text] [Related]
10. The c-myc apoptotic response is not intrinsic to blocking terminal myeloid differentiation.
D'Angelo S; Liebermann D; Hoffman B
J Cell Physiol; 2008 Jul; 216(1):120-7. PubMed ID: 18247372
[TBL] [Abstract][Full Text] [Related]
11. Cell type-specific conditional regulation of the c-myc proto-oncogene by combining Cre/loxP recombination and tamoxifen-mediated activation.
Jäger R; Maurer J; Jacob A; Schorle H
Genesis; 2004 Mar; 38(3):145-50. PubMed ID: 15048812
[TBL] [Abstract][Full Text] [Related]
12. c-myc activates RCC1 gene expression through E-box elements.
Tsuneoka M; Nakano F; Ohgusu H; Mekada E
Oncogene; 1997 May; 14(19):2301-11. PubMed ID: 9178906
[TBL] [Abstract][Full Text] [Related]
13. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
14. c-Myc protein is stabilized by fibroblast growth factor 2 and destabilized by ACTH to control cell cycle in mouse Y1 adrenocortical cells.
Lepique AP; Moraes MS; Rocha KM; Eichler CB; Hajj GN; Schwindt TT; Armelin HA
J Mol Endocrinol; 2004 Dec; 33(3):623-38. PubMed ID: 15591023
[TBL] [Abstract][Full Text] [Related]
15. Bax is a transcriptional target and mediator of c-myc-induced apoptosis.
Mitchell KO; Ricci MS; Miyashita T; Dicker DT; Jin Z; Reed JC; El-Deiry WS
Cancer Res; 2000 Nov; 60(22):6318-25. PubMed ID: 11103792
[TBL] [Abstract][Full Text] [Related]
16. Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle.
Hengstschläger M; Hölzl G; Hengstschläger-Ottnad E
Oncogene; 1999 Jan; 18(3):843-8. PubMed ID: 9989838
[TBL] [Abstract][Full Text] [Related]
17. Differential activity of conditional MYC and its variant MYC-S in human mortal fibroblasts.
Hirst SK; Grandori C
Oncogene; 2000 Oct; 19(45):5189-97. PubMed ID: 11064456
[TBL] [Abstract][Full Text] [Related]
18. c-myc-enhanced S phase entry in keratinocytes is associated with positive and negative effects on cyclin-dependent kinases.
Alexandrow MG; Moses HL
J Cell Biochem; 1998 Sep; 70(4):528-42. PubMed ID: 9712150
[TBL] [Abstract][Full Text] [Related]
19. Effects of c-MYC activation on glucose stimulus-secretion coupling events in mouse pancreatic islets.
Pascal SM; Guiot Y; Pelengaris S; Khan M; Jonas JC
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E92-102. PubMed ID: 18413670
[TBL] [Abstract][Full Text] [Related]
20. Identification of AKT-regulated genes in inducible MERAkt cells.
Kuhn I; Bartholdi MF; Salamon H; Feldman RI; Roth RA; Johnson PH
Physiol Genomics; 2001 Dec; 7(2):105-14. PubMed ID: 11773597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
